company background image
INFI

Infinity Pharmaceuticals NasdaqGS:INFI Stock Report

Last Price

US$0.55

Market Cap

US$49.0m

7D

-1.1%

1Y

-72.3%

Updated

30 Nov, 2022

Data

Company Financials +
INFI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

INFI Stock Overview

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.

Infinity Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Infinity Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.55
52 Week HighUS$2.81
52 Week LowUS$0.46
Beta1.39
1 Month Change-55.75%
3 Month Change-63.42%
1 Year Change-72.29%
3 Year Change-56.79%
5 Year Change-67.91%
Change since IPO-96.46%

Recent News & Updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18
Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15
Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11
Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Shareholder Returns

INFIUS BiotechsUS Market
7D-1.1%2.3%1.5%
1Y-72.3%-10.2%-14.8%

Return vs Industry: INFI underperformed the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: INFI underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is INFI's price volatile compared to industry and market?
INFI volatility
INFI Average Weekly Movement15.4%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: INFI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: INFI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199523Adelene Perkinshttps://www.infi.com

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Infinity Pharmaceuticals, Inc. Fundamentals Summary

How do Infinity Pharmaceuticals's earnings and revenue compare to its market cap?
INFI fundamental statistics
Market CapUS$49.02m
Earnings (TTM)-US$46.79m
Revenue (TTM)US$2.50m

19.6x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INFI income statement (TTM)
RevenueUS$2.50m
Cost of RevenueUS$33.45m
Gross Profit-US$30.95m
Other ExpensesUS$15.84m
Earnings-US$46.79m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin-1,237.47%
Net Profit Margin-1,870.85%
Debt/Equity Ratio0%

How did INFI perform over the long term?

See historical performance and comparison